Tesaglitazar (CAS 251565-85-2)

Tesaglitazar (CAS 251565-85-2) References

1. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.  |  Hegarty, BD., et al. 2004. Endocrinology. 145: 3158-64. PMID: 15059948
2. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  |  Ericsson, H., et al. 2004. Drug Metab Dispos. 32: 923-9. PMID: 15319332
3. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.  |  Fagerberg, B., et al. 2005. Diabetologia. 48: 1716-25. PMID: 16001233
4. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.  |  Oakes, ND., et al. 2005. Am J Physiol Regul Integr Comp Physiol. 289: R938-46. PMID: 16183630
5. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.  |  Zadelaar, AS., et al. 2006. Arterioscler Thromb Vasc Biol. 26: 2560-6. PMID: 16931788
6. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.  |  Goldstein, BJ., et al. 2006. Curr Med Res Opin. 22: 2575-90. PMID: 17166340
7. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.  |  Cha, DR., et al. 2007. Diabetes. 56: 2036-45. PMID: 17536062
8. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.  |  Schuster, H., et al. 2008. Atherosclerosis. 197: 355-62. PMID: 17631296
9. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.  |  Bays, H., et al. 2007. Diab Vasc Dis Res. 4: 181-93. PMID: 17907108
10. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.  |  Wilding, JP., et al. 2007. Diab Vasc Dis Res. 4: 194-203. PMID: 17907109
11. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.  |  Hamrén, B., et al. 2008. Clin Pharmacol Ther. 84: 228-35. PMID: 18388881
12. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.  |  van der Hoorn, JW., et al. 2009. Br J Pharmacol. 156: 1067-75. PMID: 19220285
13. PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.  |  Blednov, YA., et al. 2016. Alcohol Clin Exp Res. 40: 563-71. PMID: 26857541
14. Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis.  |  DeRidder, L., et al. 2021. Nanoscale. 13: 939-952. PMID: 33479718
15. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice.  |  Quarta, C., et al. 2022. Nat Metab. 4: 1071-1083. PMID: 35995995